133 related articles for article (PubMed ID: 38223616)
21. Pneumococcal conjugate vaccine primes mucosal immune responses to pneumococcal polysaccharide vaccine booster in Papua New Guinean children.
Orami T; Ford R; Kirkham LA; Thornton R; Corscadden K; Richmond PC; Pomat WS; van den Biggelaar AHJ; Lehmann D;
Vaccine; 2020 Nov; 38(50):7977-7988. PubMed ID: 33121845
[TBL] [Abstract][Full Text] [Related]
22. Comparison of the safety and immunogenicity of a pneumococcal conjugate with a licensed polysaccharide vaccine in human immunodeficiency virus and non-human immunodeficiency virus-infected children.
King JC; Vink PE; Farley JJ; Parks M; Smilie M; Madore D; Lichenstein R; Malinoski F
Pediatr Infect Dis J; 1996 Mar; 15(3):192-6. PubMed ID: 8852905
[TBL] [Abstract][Full Text] [Related]
23. Immunologic priming of young children by pneumococcal glycoprotein conjugate, but not polysaccharide, vaccines.
O'Brien KL; Steinhoff MC; Edwards K; Keyserling H; Thoms ML; Madore D
Pediatr Infect Dis J; 1996 May; 15(5):425-30. PubMed ID: 8724065
[TBL] [Abstract][Full Text] [Related]
24. Safety and immunogenicity of a new 13-valent pneumococcal conjugate vaccine versus a licensed 7-valent pneumococcal conjugate vaccine: a study protocol of a randomised non-inferiority trial in China.
Chen JJ; Yuan L; Huang Z; Shi NM; Zhao YL; Xia SL; Li GH; Li RC; Li YP; Yang SY; Xia JL
BMJ Open; 2016 Oct; 6(10):e012488. PubMed ID: 27798013
[TBL] [Abstract][Full Text] [Related]
25. Epidemiology of invasive bacterial infections in pneumococcal conjugate vaccine-vaccinated and -unvaccinated children under 5 years of age in Soweto, South Africa: a cohort study from a high-HIV burden setting.
Johnstone SL; Moore DP; Klugman KP; Madhi SA; Groome MJ
Paediatr Int Child Health; 2020 Feb; 40(1):50-57. PubMed ID: 31156062
[No Abstract] [Full Text] [Related]
26. Parental knowledge, attitudes and perception of pneumococcal disease and pneumococcal conjugate vaccines in Singapore: a questionnaire-based assessment.
How CH; Phua See Chun P; Shafi F; Jakes RW
BMC Public Health; 2016 Sep; 16(1):923. PubMed ID: 27590503
[TBL] [Abstract][Full Text] [Related]
27. Safety, tolerability, and immunogenicity of 15-valent pneumococcal conjugate vaccine in healthy adults.
McFetridge R; Meulen AS; Folkerth SD; Hoekstra JA; Dallas M; Hoover PA; Marchese RD; Zacholski DM; Watson WJ; Stek JE; Hartzel JS; Musey LK
Vaccine; 2015 Jun; 33(24):2793-9. PubMed ID: 25913828
[TBL] [Abstract][Full Text] [Related]
28. Declining serotype coverage of new pneumococcal conjugate vaccines relating to the carriage of Streptococcus pneumoniae in young children.
Tocheva AS; Jefferies JM; Rubery H; Bennett J; Afimeke G; Garland J; Christodoulides M; Faust SN; Clarke SC
Vaccine; 2011 Jun; 29(26):4400-4. PubMed ID: 21504773
[TBL] [Abstract][Full Text] [Related]
29. Immunogenicity and safety of a 13-valent pneumococcal conjugate vaccine administered to older infants and children naïve to pneumococcal vaccination.
Wysocki J; Brzostek J; Szymański H; Tetiurka B; Toporowska-Kowalska E; Wasowska-Królikowska K; Sarkozy DA; Giardina PC; Gruber WC; Emini EA; Scott DA
Vaccine; 2015 Mar; 33(14):1719-25. PubMed ID: 25698485
[TBL] [Abstract][Full Text] [Related]
30. Estimated impact of revising the 13-valent pneumococcal conjugate vaccine schedule from 2+1 to 1+1 in England and Wales: A modelling study.
Choi YH; Andrews N; Miller E
PLoS Med; 2019 Jul; 16(7):e1002845. PubMed ID: 31269018
[TBL] [Abstract][Full Text] [Related]
31. Quality of antibody responses by adults and young children to 13-valent pneumococcal conjugate vaccination and Streptococcus pneumoniae colonisation.
Wolf AS; Mitsi E; Jones S; Jochems SP; Roalfe L; Thindwa D; Meiring JE; Msefula J; Bonomali F; Makhaza Jere T; Mbewe M; Collins AM; Gordon SB; Gordon MA; Ferreira DM; French N; Goldblatt D; Heyderman RS; Swarthout TD
Vaccine; 2022 Nov; 40(50):7201-7210. PubMed ID: 36210249
[TBL] [Abstract][Full Text] [Related]
32. Comparison of anti-capsular antibody quantity and functionality in children after different primary dose and booster schedules of 13 valent-pneumococcal conjugate vaccine.
Kaur R; Pichichero M
Vaccine; 2020 Jun; 38(28):4423-4431. PubMed ID: 32402752
[TBL] [Abstract][Full Text] [Related]
33. Adherence to pneumococcal conjugate vaccination schedule and uptake rate as compared to the established diphtheria-tetanus-acellular pertussis vaccination in Cyprus.
Hadjipanayis A; Efstathiou E; Michaelidou K; Papaevangelou V
Vaccine; 2018 Sep; 36(38):5685-5691. PubMed ID: 30115523
[TBL] [Abstract][Full Text] [Related]
34. Impact of pneumococcal conjugate vaccine on invasive pneumococcal disease in children under 5 years of age in the Czech Republic.
Kozakova J; Krizova P; Maly M
PLoS One; 2021; 16(2):e0247862. PubMed ID: 33635933
[TBL] [Abstract][Full Text] [Related]
35. Pneumococcal conjugate vaccine-elicited antibody persistence and immunogenicity and safety of 13-valent pneumococcal conjugate vaccine in children previously vaccinated with 4 doses of either 7-valent or 13-valent pneumococcal conjugate vaccine.
Quinet B; Laudat F; Gurtman A; Patterson S; Sidhu M; Gruber WC; Scott DA
Pediatr Infect Dis J; 2014 Oct; 33(10):1065-76. PubMed ID: 25093973
[TBL] [Abstract][Full Text] [Related]
36. A randomized, open-label, phase 3 study evaluating safety and immunogenicity of 13-valent pneumococcal conjugate vaccine in Chinese infants and children under 6 years of age.
Chu K; Hu Y; Pan H; Wu J; Zhu D; Young MM; Luo L; Yi Z; Giardina PC; Gruber WC; Scott DA; Watson W
Hum Vaccin Immunother; 2023 Aug; 19(2):2235926. PubMed ID: 37549923
[No Abstract] [Full Text] [Related]
37. Safety and immunogenicity of a heptavalent pneumococcal conjugate vaccine in infants with human immunodeficiency virus type 1 infection.
Nachman S; Kim S; King J; Abrams EJ; Margolis D; Petru A; Shearer W; Smith E; Moye J; Blanchard S; Hawkins E; Bouquin P; Vink P; Benson M; Estep S; Malinoski F;
Pediatrics; 2003 Jul; 112(1 Pt 1):66-73. PubMed ID: 12837869
[TBL] [Abstract][Full Text] [Related]
38. Immunogenicity, otitis media, hearing impairment, and nasopharyngeal carriage 6-months after 13-valent or ten-valent booster pneumococcal conjugate vaccines, stratified by mixed priming schedules: PREVIX_COMBO and PREVIX_BOOST randomised controlled trials.
Leach AJ; Wilson N; Arrowsmith B; Beissbarth J; Mulholland EK; Santosham M; Torzillo PJ; McIntyre P; Smith-Vaughan H; Chatfield MD; Lehmann D; Binks M; Chang AB; Carapetis J; Krause V; Andrews R; Snelling T; Skull SA; Licciardi PV; Oguoma VM; Morris PS
Lancet Infect Dis; 2022 Sep; 22(9):1374-1387. PubMed ID: 35772449
[TBL] [Abstract][Full Text] [Related]
39. Carriage prevalence and serotype distribution of Streptococcus pneumoniae prior to 10-valent pneumococcal vaccine introduction: A population-based cross-sectional study in South Western Uganda, 2014.
Nackers F; Cohuet S; le Polain de Waroux O; Langendorf C; Nyehangane D; Ndazima D; Nanjebe D; Karani A; Tumwesigye E; Mwanga-Amumpaire J; Scott JAG; Grais RF
Vaccine; 2017 Sep; 35(39):5271-5277. PubMed ID: 28784282
[TBL] [Abstract][Full Text] [Related]
40. Immunogenicity and safety of single-dose, 13-valent pneumococcal conjugate vaccine in pediatric and adolescent oncology patients.
Hung TY; Kotecha RS; Blyth CC; Steed SK; Thornton RB; Ryan AL; Cole CH; Richmond PC
Cancer; 2017 Nov; 123(21):4215-4223. PubMed ID: 28696530
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
